{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:06:39Z","timestamp":1758636399495},"reference-count":94,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T00:00:00Z","timestamp":1278460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM). A number of new therapies with precise targets involved in MM cell growth and replication are now in development and have the potential for further improvements. Second\u2010generation proteasome inhibitors and thalidomide derivatives may offer increased efficacy and safety. Investigational therapies with rationally selected targets in MM include inhibitors of histone deacetylase, heat shock protein 90, mammalian target of rapamycin, BCL2, Akt, mitogen\u2010activated protein kinase, and telomerase. In addition, monoclonal antibodies directed against several targets have been developed and many are showing promise in initial clinical trials in MM. Interest in the ancient remedy of arsenic trioxide has been revived because of its proapoptotic effects on mitochondria, despite its established toxicities. In general, combination regimens are proving the most efficacious, which is to be expected given the multiple overlapping pathways responsible for MM growth and progression.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08262.x","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T01:52:17Z","timestamp":1278553937000},"page":"3-15","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of target\u2010specific treatments in multiple myeloma"],"prefix":"10.1111","volume":"151","author":[{"given":"Asher A.","family":"Chanan\u2010Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna E.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.024"},{"key":"e_1_2_7_3_1","first-page":"465s","article-title":"Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)","volume":"26","author":"Anderson K.C.","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.381"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2850"},{"key":"e_1_2_7_6_1","first-page":"742","article-title":"Tanespimycin + bortezomib in relapsed\/refractory myeloma patients: results from the TIME\u20102 study","volume":"114","author":"Badros A.Z.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_7_1","first-page":"3658","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid\u2010mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis N.J.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_7_8_1","first-page":"313","article-title":"Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells","volume":"30","author":"Baysan A.","year":"2007","journal-title":"International Journal of Oncology"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0182"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604388"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.06.023"},{"key":"e_1_2_7_12_1","first-page":"121","article-title":"Bortezomib (Velcade\u00ae)\u2010thalidomide\u2010dexamethasone (VTD) vs thalidomide\u2010dexamethasone (TD) in preparation for autologous stem\u2010cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"110","author":"Cavo M.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_13_1","first-page":"1263","article-title":"Phase I Study of IMGN901 in Patients with Relapsed and Relapsed\/Refractory CD56\u2010Positive Multiple Myeloma","volume":"112","author":"Chanan\u2010Khan A.A.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_14_1","first-page":"1263","article-title":"Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)","volume":"112","author":"Chanan\u2010Khan A.A.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902748971"},{"key":"e_1_2_7_16_1","first-page":"454s","article-title":"Targeting Cdk4\/6 in combination therapy of chemoresistant multiple myeloma","volume":"26","author":"Chen\u2010Kiang S.","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1667"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903207548"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802699332"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.10.010"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-053728"},{"key":"e_1_2_7_22_1","first-page":"1","article-title":"Histone deacetylase inhibitors in multiple myeloma","volume":"1","author":"Deleu S.","year":"2009","journal-title":"Hematology Reviews"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161206775201974"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902953699"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.039"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1483"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0793-8"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/pr9001004"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0511"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05914.x"},{"key":"e_1_2_7_32_1","first-page":"659a","article-title":"Bortezomib (VelcadeTM) + adriamycinTM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM)","volume":"104","author":"Hollmig K.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2867"},{"key":"e_1_2_7_35_1","first-page":"460s","article-title":"Long\u2010term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma","volume":"26","author":"Jagannath S.","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_36_1","first-page":"435s","article-title":"Final results of PX\u2010171\u2010003\u2010A0, part 1 of an open\u2010label, single\u2010arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"27","author":"Jagannath S.","year":"2009","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_37_1","first-page":"1264","article-title":"Phase I results of perifosine (KRX\u20100401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)","volume":"112","author":"Jakubowiak A.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_38_1","first-page":"438s","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I\/II MMRC trial","volume":"27","author":"Jakubowiak A.J.","year":"2009","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_39_1","first-page":"1491","article-title":"Phase 1\/2 study of elotuzumab in combination with bortezomib in patients with multiple myeloma with one to three prior therapies: interim results","volume":"114","author":"Jakubowiak A.J.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01913"},{"key":"e_1_2_7_41_1","first-page":"244","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS) an analysis of the Greek Myeloma Study Group (GMSG)","volume":"112","author":"Kastritis E.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.01.004"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152009788451851"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.08.001"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_2_7_46_1","first-page":"660a","article-title":"Prognostic Value of Syndecan\u20101 in Multiple Myeloma and its Relationship with Other Prognostic Factors","volume":"104","author":"Kumar S.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_47_1","first-page":"951a","article-title":"Serum Soluble Syndecan\u20101 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages","volume":"106","author":"Kyrtsonis M.\u2010C.","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.37"},{"key":"e_1_2_7_49_1","first-page":"320","article-title":"Pomalidomide (CC4047) plus low\u2010dose dexamethasone (pom\/dex) is highly effective therapy in relapsed multiple myeloma","volume":"112","author":"Lacy M.Q.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"e_1_2_7_51_1","first-page":"179","article-title":"Phase 1\/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results","volume":"114","author":"Lonial S.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114348"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.6.10029"},{"key":"e_1_2_7_54_1","first-page":"186a","article-title":"Syndecan\u20101 Is Essential for the Myeloma Cell Growth Factor Activity of EGF\u2010Family Ligands in Multiple Myeloma","volume":"106","author":"Mahtouk K.","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2004.01834.x"},{"key":"e_1_2_7_56_1","first-page":"1268","article-title":"Final results of a phase II trial with plitidepsin (Aplidin\u00ae) alone and in combination with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"112","author":"Mateos M.\u2010V.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4285"},{"key":"e_1_2_7_58_1","first-page":"3827","article-title":"p38alpha\u2010selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma","volume":"28","author":"Medicherla S.","year":"2008","journal-title":"Anticancer Research"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07409.x"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5725"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.02.003"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488706778250050"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70304-8"},{"key":"e_1_2_7_66_1","first-page":"437s","article-title":"A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients","volume":"27","author":"Palumbo A.P.","year":"2009","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721060-00005"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0561"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.12.4.463"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707374"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0572"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.019"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2007.07.001"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0483"},{"key":"e_1_2_7_75_1","first-page":"41","article-title":"Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I\/II study","volume":"112","author":"Richardson P.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701817258"},{"key":"e_1_2_7_77_1","first-page":"321","article-title":"Phase I\/II results of a multicenter trial of perifosine (KRX\u20100401) + bortezomib in patients with relapsed or relapsed\/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib","volume":"112","author":"Richardson P.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_2_7_79_1","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2009.27.15_suppl.8503","article-title":"Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I\/II study","volume":"27","author":"Richardson P.G.","year":"2009","journal-title":"American Society of Clinical Oncology (ASCO)"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198408"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.04.007"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.07.007"},{"key":"e_1_2_7_83_1","first-page":"99","article-title":"AT7519, a novel small molecule multi\u2010cyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3{beta}","volume":"112","author":"Santo L.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.388"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.81"},{"key":"e_1_2_7_86_1","first-page":"1022a","article-title":"Phase II trial of SCIO\u2010469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM)","volume":"108","author":"Siegel D.S.","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07976.x"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-5"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0142"},{"key":"e_1_2_7_91_1","unstructured":"U.S. National Institutes of Health.2009A study of tanespimycin (KOS\u2010953) in patients with relapsed\u2010refractory multiple myeloma (TIME\u20102).http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00514371. Accessed 25 August 2009."},{"key":"e_1_2_7_92_1","first-page":"443s","article-title":"PX\u2010171\u2010004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update","volume":"27","author":"Vij R.","year":"2009","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_93_1","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/jco.2008.26.15_suppl.8593","article-title":"Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed\/refractory multiple myeloma (MM)","volume":"26","author":"Voorhees P.M.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_94_1","first-page":"322","article-title":"Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: early clinical experience","volume":"112","author":"Weber D.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1716"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08262.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08262.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:54:06Z","timestamp":1697424846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08262.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,7]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08262.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08262.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,7]]},"assertion":[{"value":"2010-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}